NTLA / Intellia Therapeutics Will Soon Make Biotech History. Is the Stock a Buy?

Intellia will soon start a phase 3 gene-editing trial, the first of its kind. Succeeding with the trial will not be the last hurdle it needs to overco more_horizontal

Intellia's (NTLA) in-vivo CRISPR-based gene-edited therapy candidate NTLA-2001 holds potential. Other pipeline candidates are in early-stage developme more_horizontal

Intellia (NTLA) gets FDA nod to begin a phase III study on its gene editing candidate, NTLA-2001 to treat transthyretin amyloidosis with cardiomyopath more_horizontal

The European Medicines Agency bestows a Priority Medicines (PRIME) designation to Intellia's (NTLA) in vivo CRISPR-based investigational therapy, NTLA more_horizontal

Intellia has declined over the past year even as its candidates for severe diseases have advanced in clinical studies. The company aims to launch a ph more_horizontal

Intellia's leading candidates look promising, but there's a long way to go before they hit the market. If the company can deliver regular clinical and more_horizontal

Intellia Therapeutics has a pair of promising gene-editing therapies in the works. It also has a highly technically advanced program that could enter more_horizontal

Regeneron Pharmaceuticals and Intellia Therapeutics have expanded their research collaboration to develop additional CRISPR-based gene editing therapi more_horizontal